KDR (基因名), Vascular endothelial growth factor receptor 2 (蛋白名), vgfr2_human.
产品名称:
Human KDR/ Vascular endothelial growth factor receptor 2 Recombinant Protein
血管内皮细胞生长因子受体2
货号:
R0148h
商标:
EIAab®
监管等级:
别名:
Fetal liver kinase 1, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1, FLK-1, KDR, CD309, VEGFR-2, FLK1, VEGFR2
序列号:
P35968
来源:
E.coli
种属:
Human
标签:
His
纯度:
>90% by SDS-PAGE
浓度:
Reconstitution Dependent
形态:
Liquid
内毒素水平:
Please contact protein@eiaab.com The technician for more information.
应用:
存储缓冲液:
50mM NaH2PO4, 500mM NaCl Buffer with 500mM Imidazole, 10%glycerol(PH8.0)
存储:
Store at -20°C. (Avoid repeated freezing and thawing.)
研究领域:
-
R&D 技术数据
更多信息，请参阅手册，或联系我们的技术支持: tech@eiaab.com.
基因位点
KDR Gene in genomic location: bands according to Ensembl, locations according to GeneLoc (and/or Entrez Gene and/or Ensembl if different)
通用注释
亚单元:
Homodimer in the presence of bound dimeric VEGFA, VEGFC or VEGFD ligands; monomeric in the absence of bound ligands. Can also form heterodimers with FLT1/VEGFR1 and FLT4/VEGFR2. Interacts (tyrosine phosphorylated) with LFYN, NCK1, PLCG1. Interacts (tyrosine-phosphorylated active form preferentially) with DAB2IP (via C2 domain and active form preferentially); the interaction occurs at the late phase of VEGFA response and inhibits KDR/VEGFR2 activity. Interacts with SHBSH2D2A/TSAD, GRB2, MYOF, CBL and PDCD6. Interacts with HIV-1 Tat (PubMed:10102632, PubMed:10590123, PubMed:12649282, PubMed:12881528, PubMed:1417831, PubMed:15026417, PubMed:15215251, PubMed:15837294, PubMed:15962004, PubMed:16966330, PubMed:17253678, PubMed:18529047, PubMed:18593464, PubMed:19033661, PubMed:19668192, PubMed:20080685, PubMed:20145116, PubMed:20224550, PubMed:20705758, PubMed:21827946, PubMed:21893193, PubMed:9160888). Interacts (via C-terminus domain) with ERN1 (via kinase domain); the interaction is facilitated in a XBP1 isoform 1- and vascular endothelial growth factor (VEGF)-dependent manner in endothelial cells (PubMed:23529610).
功能:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
亚细胞位置:
Isoform 3
Secreted
数据库链接
验证序列:
该产品尚未在任何出版物中被引用。
[1].
"Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor."
[2].
"Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling."
[3].
"Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy."
[4].
"VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2."
[5].
"The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer."
[6].
"New role for the protein tyrosine phosphatase DEP-1 in Akt activation and endothelial cell survival."
[7].
"Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes."
[8].
"Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100."
[9].
"A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer."
[10].
"Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF."
[1].
人血管内皮细胞生长因子受体2(KDR)重组蛋白是否是无菌的？
蛋白试剂瓶和蛋白保存液是经过高压灭菌的，但也不能保证蛋白是完全无菌的。如果要求蛋白是无菌的，可以用0.2微米的滤器对蛋白进行过滤。
[2].
人血管内皮细胞生长因子受体2(KDR)重组蛋白的保存缓冲液是什么？
纯化后的蛋白保存在PBS（58mM Na2HPO4, 17mM NaH2PO4, 68mM NaCl, pH7.4）里，并往里面加入500mM咪唑和10%甘油。
[3].
怎样确定人血管内皮细胞生长因子受体2(KDR)重组蛋白的浓度？
蛋白浓度的确定没有一个统一的标准，这主要取决于蛋白的氨基酸序列。伊艾博是根据不同测试的组合来测定蛋白浓度。考马斯亮蓝法、BCA法、氨基酸序列和氨基酸全序列分析法等都用来测定蛋白浓度。
[4].
人血管内皮细胞生长因子受体2(KDR)重组蛋白蛋白保存条件是怎样的？
蛋白应保存在 -20℃或 -80℃条件下，为了避免反复冻融，可以将蛋白分装成小份保存。
[5].
人血管内皮细胞生长因子受体2(KDR)重组蛋白是否可以用于活体实验？
重组蛋白没有用于任何的活体实验，因此蛋白的活性和半衰期是不确定的。
[6].
人血管内皮细胞生长因子受体2(KDR)重组蛋白的保质期是多久？
在适当的保存条件下，从购买之日起蛋白可以稳定保存6-12个月。适当的保存条件是:蛋白保存在-20°C o或 -80℃，保证蛋白的保存浓度高于0.1mg/ml，限制蛋白反复冻融的次数。我们公司常规的质量检测保证所有产品在销售时都有可接受的生物活性。但是我们不能控制终端用户蛋白的保存条件。如果产品在有效期内出现问题，请联系我们的技术支持。
[7].
你们蛋白和抗体的报价是怎么样的？
我们将根据你需要的蛋白和抗体的大小进行报价。
[8].
人血管内皮细胞生长因子受体2(KDR)重组蛋白是否能够提供蛋白片段？
我们现有的人的蛋白的序列可以有很多。你可以选择你感兴趣的靶向部分，我们将会按您的需求提供蛋白和抗体。
[9].
人血管内皮细胞生长因子受体2(KDR)重组蛋白的货期或发货时间一般是多长？
具体指标的货期需要确定。最快一周，最长可能一个月。
反馈墙
评论数 : 0
所有用户
所有用户
默认排序
默认排序
最近
早期
目前还没有评论。
通知
规格
数量
单价 (￥)
小计 1 (￥)
小计 2:
￥
规格
数量
单价 (￥)
折扣:
请选择至少一个规格!